Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M-HA 30 Architect (M-HA®30 Architect) is an injectable medical device developed by Laboratoires FILL-MED for aesthetic skin rejuvenation. It is a next-generation, boosted formulation of M-HA 10, featuring a higher concentration of non-crosslinked, non-animal sodium hyaluronate (hyaluronic acid) and the addition of Silicium, a chemical element naturally present in the body. The product is designed for intradermal injection to improve skin quality parameters, including hydration, radiance, and elasticity, specifically on the face, neck, and décolleté. Unlike traditional crosslinked dermal fillers used for deep volume restoration, M-HA 30 Architect functions as a skin booster to replenish the skin's natural hyaluronic acid levels and structural integrity. It is currently undergoing clinical evaluation in the HEBE8 trial to support CE marking for aesthetic indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on M-HA 30 Architect.